Home About STOP Members CIMH-CAP

Zentralinstitut für Seelische Gesundheit, Dept. of Child and Adolescent Psychiatry and Psychotherapy


Central Institute of Mental Health
Department of Child and Adolescent Psychiatry and Psychotherapy
J 5
D-68159 Mannheim, Germany


Project leader

Prof. Dr. Dr. Tobias Banaschewski, MD, PhD

Prof. Dr. Dr. Tobias Banaschewski, MD, PhD
Medical Director

Phone: +49 (0) 621/1703 4502
Fax: +49 (0) 621/1703 4505
Prof. Dr. Dr. Ralf W. Dittmann, MD, PhD

Prof. Dr. Dr. Ralf W. Dittmann, MD, PhD
Professor of Paediatric Psychopharmacology

Phone: +49 (0) 621/1703 4941
Fax: +49 (0) 621/1703 4945

Project staff

Dr. Alexander Häge, MD

Phone: +49 (0) 621 1703 4924
Fax: +49 (0) 621 1703 4945

Ruth Berg, MSc
Study coordinator

Phone: +49 (0) 621 1703 4541
Fax: +49 (0) 621 1703 4545

Konstantin Mechler

Phone: +49 (0) 621 1703 4924
Fax: +49 (0) 621 1703 4945

Dr. Mahmud Ben Dau

Phone: +49 (0) 621 1703 4943
Fax: +49 (0) 621 1703 4945

Institute presentation

Description of organisation:

The University of Heidelberg is a leading German institute for medical research. The Central Institute of Mental Health (CIMH) is a globally recognised centre of modern psychiatry delivering outstanding science, research and teaching in partnership with institutions at home and abroad. Since 1980 the Institute is a Collaborating Centre for Research and Training in Mental Health of the WHO.

The Department of Child and Adolescent Psychiatry and Psychotherapy, headed by Prof. Tobias Banaschewski, MD, PhD, at the Central Institute of Mental Health (CIMH) is specialized in top-level psychiatric treatment and research in neuropsychiatric disorders (e.g., ADHD, Conduct Disorders, Tourette Syndrome,  Autism). Research on efficacy and safety of medication treatment for psychiatric disorders in youths is a main focus of the department’s research agenda.

In the summer of 2008, the Eli Lilly Endowed Chair for Paediatric Psychopharmacology has been established at CAP CIMH, as a specialized branch unique in German academic child & adolescent psychiatry, focussing on clinical research with psychotropic compounds in children and adolescents. This unit is run by Prof. Ralf W. Dittmann, MD, PhD.

The Department of Child and Adolescent Psychiatry/¬Psychotherapy is equipped with 52 inpatient beds distributed in 4 units/wards plus an outpatient facility. The department has access to approximately 1800 new patients a year. The team consists of 6 child and adolescent psychiatrists, 14 residents, and 11 (clinical) psychologists.

Previous experience:

CAP CIMH and been involved in several international collaborations including various multisite medication trials. T. Banaschewski has been the principle investigator in several research projects including a current registration trial for a new ADHD compound. R.W. Dittmann has been serving as a director and leading clinical researcher within an international pharmaceutical company, focussing on the national and international development and registration of various psychotropic compounds, e.g., for the treatment of ADHD, schizophrenia, and bipolar disorder in children and adolescents.

The CIMH also has solid experience in the management and implementation of earlier EU FP projects.

Profile of staff members:

Tobias Banaschewski (MD, PhD) is an expert in research on neurobiology and neuropsychology of ADHD and associated child psychiatric disorders. He is currently Co-Principal Investigator of the NIMH-funded International Multi-Centre ADHD Genetics Project and is a member of the Advisory Board of the European Network of Research on Hyperkinetic Disorders. He was awarded the Kramer-Pollnow-Award for research on ADHD in 2003. He is the Co-editor of JCPP and Member of the Eunethydis Guidelines Group on diagnosis and treatment of ADHD. He is also the director of the Department of Child and Adolescent Psychiatry and Psychotherapy, CIMH, Mannheim, and holds a chair at the University of Heidelberg.

Ralf W. Dittmann (MD, PhD) is a child and adolescent psychiatrist, clinical psychologist, and Professor of Paediatric Psychopharmacology, also a recipient of the H. Emminghaus award. He has been responsible for more that 70 clinical trials including the role of principal investigator.

Main tasks in this project:

This partner is responsible for the WP8, protocol development, implementation, execution, analyses, and publication of the ‘Prospective Cohort Study of Depressed Adolescents on Fluoxetine’. In addition, CAP CIMH will participate and contribute to both the methodology work packages 3 and 4, and also actively recruit and study patients in the Prospective Cohort Study using the PERS Study subjects (WP7).

Research with relevance to the project:

  1. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009 70(2):247-58.
  2. Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E,
    Mästele A, Wehmeier PM. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol. 2008 18(1):54-69.
  3. Dittmann RW, Czekalla J, Hundemer HP, Linden M. Efficacy and safety findings from naturalistic fluoxetine drug treatment in adolescent and young adult
    patients. J Child Adolesc Psychopharmacol. 2000 10(2):91-102.
  4. Dittmann RW, Linden M, Osterheider M. Fluoxetine treatment and single psychotropic comedication: is there an increase in adverse event rates? Pharmacoepidemiol Drug Saf. 1998 7(3):197-206.